Roche's Fenebrutinib Shines in Phase III Trials for Multiple Sclerosis

Roche (SIX:ROG) has made waves with fresh Phase III trial results for fenebrutinib, its experimental oral treatment aimed at multiple sclerosis (MS). This twice-daily pill demonstrated a clear edge in reducing relapses among those with relapsing MS, while also showing promise in halting disability progression in primary progressive MS.

The FENhance 2 trial, focusing on relapsing multiple sclerosis patients, saw fenebrutinib significantly outperform teriflunomide by lowering the annual relapse rate after around two years of treatment. Over in the FENtrepid study - targeting primary progressive MS - fenebrutinib also didn't disappoint, matching Roche's existing drug OCREVUS in delaying confirmed disability progression over approximately 120 weeks.

Interestingly, fenebrutinib's benefits in progressive MS became noticeable within the first 24 weeks and stuck around throughout the observation period, suggesting durability in effect. Roche's chief medical officer, Levi Garraway, put it plainly: these "unprecedented results" could position fenebrutinib as the pioneering oral, high-efficacy treatment covering both MS types.

Safety data so far keeps pace with earlier studies, particularly concerning liver health, while Roche continues analyzing additional safety details. The firm aims to report results from its other Phase III relapsing MS trial, FENhance 1, in early 2026, which will pave the way for regulatory submissions.

Fenebrutinib's mechanism of action targets two immune cells playing key roles in MS - B cells that spark inflammation and microglia involved in ongoing brain damage. Its design as a reversible, non-covalent Bruton's tyrosine kinase inhibitor enables it to cross the blood-brain barrier, a prized ability for MS drugs. The molecule boasts notable selectivity, over 130 times more for BTK compared to other enzymes.

The trials pooled nearly 2,500 patients across the two forms of MS, with participants randomly assigned to fenebrutinib or established comparators for lengthy study periods exceeding two years. Measurements focused on relapse rates, disability progression, and neurological assessments including walking and upper limb functionality.

MS remains a global challenge, afflicting upwards of 2.9 million people, with relapsing forms making up 85% of cases and primary progressive around 15%. Both types typically entail worsening symptoms over time, so treatment innovations that delay progression carry meaningful weight.

Roche's stock edged higher by roughly 2% in response to the news, reflecting market interest in a new contender that could shake up the MS treatment scene. Fenebrutinib's potential as the first oral, high-efficacy option that spans both relapsing and primary progressive forms might just reshape patient options in the years ahead.